Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 4, 2000, Pages 332-338

  Muga, Roberto ^a   Roca, Josep ^a   Egea, Jose Manuel ^a   Tor, Jordi ^a   Sirera, Guillem ^a   Rey Joly, Celestino ^a   Muñoz, Alvaro ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV infection; IDUs; Mortality rates; Survival

Indexed keywords

DIAMORPHINE;

ADULT; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; FEMALE; HEALTH STATUS; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0034176214     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200004010-00009     Document Type: Article

References (49)

1. Robertson JR, Ronald PJM, Raab GM, Ross AJ, Parpia T. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 1994;309:369-72.
2. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994;89:1299-1308.
3. Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med 1995;332:1753-7.
4. Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 1995;20:1467-79.
5. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe: quarterly report no. 56. Paris: European Centre for the Epidemiological Monitoring of AIDS, 1997.
6. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. The HIV epidemic associated with injecting drug use in Europe: geographic and time trends. AIDS 1997;11:1365-74.
7. Ministerio de Sanidad y Consumo. Secretaria del Plan Nacional sobre SIDA. Epidemiología del sida en España. Situación en el contexto mundial. Diciembre 1995. Mortalidad por el VIH y SIDA en España en 1992. Comparación con otras causas de defunción. Capitulo VI. Madrid: Ministerio de Sanidad y Consumo, 1995.
8. Sanchez J, Rodriguez B, de la Fuente L, et al., and the State Information System on Drug Abuse (SEIT) Working Group. Opiates or cocaine: mortality from acute reactions in six major Spanish cities. J Epidemiol Community Health 1995;49:54-60.
9. Galli M, Musicco M for the COMCAT Study Group. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. AIDS 1994;8:1457-63.
10. Zaccarelli M, Gattari P, Rezza G, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994;8:345-50.
11. Perucci CA, Forastiere F, Rapiti E, Davoli M, Abeni DD. The impact of intravenous drug use on mortality of young adults in Rome, Italy. Br J Addict 1992;87:1637-41.
12. Perucci CA, Davoli M, Rapiti E, Abani DD, Forastiere F. Mortality of intravenous drug users in Roma: a cohort study. Am J Public Health 1991;81:1307-10.
13. de la Fuente L, Barrio G, Vicente J, Bravo MJ, Santacreu J. The impact of drug-related deaths on mortality among young adults in Madrid. Am J Public Health 1995;85:102-5.
14. Orti RM, Domingo-Salvany A, Muñoz A, Macfarlane D, Suelves JM, Anto JM. Mortality trends in a cohort of opiate addicts, Catalonia, Spain. Int J Epidemiol 1996;25:545-53.
15. Van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996;143: 380-91.
16. Laurichesse HA, Mortimer J, Evans BG, Farrington CP. Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland, 1982-1996. AIDS 1998;12:651-8.
17. Fugelstad A, Annell A, Rajs J, Agren G . Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981-1992. Acta Psychiatr Scand 1997;96:169-75.
18. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997;92:419-27.
19. European Center for AIDS Surveillance. 1993 revision of the European AIDS Surveillance case definition, Report 37/1993. Paris: European Center for AIDS Surveillance, 1993:23-38.
20. Lamarca R, Alonso J, Gomez G, Muñoz A. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci 1998;53: M337-13.
21. Clayton D, Hills M. Statistical models in epidemiology. New York: Oxford University Press, 1993.
22. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-1503.
23. Muñoz A, Hoover DR. Use of cohort studies for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials. New York: John Wiley & Sons, 1995:423-46.
24. Muñoz A, Sunyer J. Comparison of semiparametric and parametric survival models for the analysis of bronchial responsiveness. Am J Respir Crit Care Med 1996;154:S234-9.
25. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 1992;11: 1871-9.
26. Hahn RA, Onorato IM, Jones S, Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989;261:2677-84.
27. Hernandez-Aguado I, Bolumar F. Determinants of HIV-1 infection in intravenous drug users in Valencia, Spain, 1987-1991. Int J Epidemiol 1993;22:537-42.
28. Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992;18:263-73.
29. Reig P, Sanz P, Marti G, Corbella J. Opioid-related deaths in Barcelona 1981-1986. Lancet 1987;2:508-9.
30. Mientjes GH, van Ameijden EJ, van den Hoek AJR, Coutinho RA. Increasing morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam. AIDS 1992; 6:207-12.
31. Prins M, Hernández-Aguado I, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997;11:1747-56.
32. Li L, Smialek JE. Observations on drug abuse deaths in the State of Maryland. J Forensic Sci 1996;41:106-9.
33. van Haastrecht HJA, Mientjes GHC, van den Hoek AJR, Coutinho RA. Death from suicide and overdose among drug injectors after disclosure of first HIV test result. AIDS 1994;8:1721-5.
34. van Haastrecht HJA, van den Hoek AJR, Coutinho RA. High mortality among HIV-infected injecting drug users without AIDS diagnosis: implications for HIV infection epidemic modellers? AIDS 1994;8:363-6.
35. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
36. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
37. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
38. Chiasson MA, Berenson L, Li W, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City (NYC). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington D.C., January 22-26, 1977. Washington, DC: IDSA Foundation for Retrovirology and Human Health, 1997:133.
39. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictor of disease progression in drug users with Human Immunodeficiency Virus infection. N Engl J Med 1992;327:1697-1703.
40. Phillips AN, Sabin CA, Mocroft A. Active drug injecting and progression of HIV infection. AIDS 1994;8:385-6.
41. Selwyn PA. Can we reduce the burden of morbidity in HIV-infected injecting drug users? AIDS 1996;10:1429-30.
42. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues 1995;25:225-33.
43. Rebagliato M, Aviño MJ, Hernandez-Aguado I, et al. Trends in incidence and prevalence of HIV-1 infection in intravenous drug users in Valencia, Spain. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:297-301.
44. Sopelana P, Dieguez A, Bautista L. Prevalencia de la infección por el virus de la inmunodeficiencia humana tipo 1 en drogodependientes de Madrid, durante un período de 5 años. Med Clin (Barc) 1991;97:601-3.
45. Bayas JM, Martin V, Vidai J, Pumarola T, Jimenez de Anta MT, Salleras L. Infeccion por el virus de la inmunodeficiencia humana tipo 1 en la población penitenciaria de Cataluña. Med Clin (Barc) 1994;102:209-12.
46. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998;316:426-8.
47. Darke S, Hall W, Weatherburn D, Lind B. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug Alcohol Depend 1999;54:155-61.
48. Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991;9: 336-342.
49. Gutierrez-Cebolleda J, de la Torre R, Ortuno J, Garces JM, Cami J. Psychotropic drug consumption and other factors associates with heroin overdose. Drug Alcohol Depend 1994;35:169-74.